BCAL Diagnostics Limited (ASX:BDX – Get Free Report) insider Jayne Shaw purchased 480,748 shares of the stock in a transaction on Wednesday, November 6th. The shares were acquired at an average cost of A$0.11 ($0.07) per share, with a total value of A$50,478.54 ($33,209.57).
Jayne Shaw also recently made the following trade(s):
- On Friday, September 13th, Jayne Shaw bought 125,000 shares of BCAL Diagnostics stock. The stock was bought at an average cost of A$0.12 ($0.08) per share, with a total value of A$14,375.00 ($9,457.24).
BCAL Diagnostics Stock Performance
The company has a current ratio of 3.60, a quick ratio of 6.70 and a debt-to-equity ratio of 17.74.
About BCAL Diagnostics
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body.
Read More
- Five stocks we like better than BCAL Diagnostics
- What is the Dogs of the Dow Strategy? Overview and Examples
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
- How to Calculate Options Profits
- Why Meta Should Rally All The Way Into 2025
- How to Buy Cheap Stocks Step by Step
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
Receive News & Ratings for BCAL Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BCAL Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
